Memory Consolidation in Pharmacologically Enhanced Naps
Information source: National Institute of Mental Health (NIMH)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sleep
Intervention: Low-dose sodium oxybate (Drug); High-dose sodium oxybate (Drug); Low-dose zolpidem (Drug); High-dose zolpidem (Drug); Placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: National Institute of Mental Health (NIMH) Official(s) and/or principal investigator(s): Sara C. Mednick, PhD, Principal Investigator, Affiliation: UCSD
Overall contact: Jen Kanady, BA, Phone: 858-642-3192, Email: jkanady@ucsd.edu
Summary
This study will examine whether various drugs affecting sleep cycles can improve different
kinds of memory.
Clinical Details
Official title: Understanding Memory Consolidation by Studying Pharmacologically Enhanced Naps.
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research
Primary outcome: Pharmacological enhancement of specific sleep parameters in a dose-dependent manner
Secondary outcome: Correlation of pharmacological interventions with changes in sleep-stage-specific memory tasks
Detailed description:
Research provides evidence for strong, specific connections between sleeping and memory.
This research shows that sleeping is necessary for certain types of memories to form,
certain sleep stages lead to specific types of learning and memory consolidation, and naps
are as effective as night-time sleep in these learning and memory processes. Current
evidence also indicates that there are different types of memory and that the different
types can operate and develop independently. In this study, three different memory types
will be examined: perceptual, motor, and declarative memory. Perceptual memory is measured
through the ability to recognize discrete stimuli; motor memory is measured through the
ability to perform specific, coordinated tasks; and declarative memory is measured through
the ability to recite memorized information. Different stages in the sleep cycle correlate
with improvements in each of these memory processes. For instance, improvement of perceptual
memory tasks is dependent on rapid eye motion (REM) sleep; motor learning is related to
sleep stage 2; and declarative memory consolidation is related to short wave sleep (SWS),
which includes sleep stages 3 and 4.
New drugs can target specific sleep stages and increase the amount of time people spend in
those stages when they sleep. For example, the new prescription drug zolpidem increases time
spent in stage 2 during sleep, and the drug sodium oxybate increases time spent in SWS.
Compared to sleep impacted by either zolpidem or sodium oxybate, normal sleep has
proportionally more time spent in REM. This study will use medications, or their lack, to
manipulate how much time is spent in REM, stage 2, and SWS. The study will then examine
whether the percentage of sleep spent in different stages affects the learning processes
associated with those stages.
Participation in this study will last 6 weeks. At the outset, participants will undergo a
2-hour screening visit that will include a medical history, a physical examination, routine
lab tests, urine tests for drugs and pregnancy, an electrocardiogram, and a clinical
interview for mental health. Participants will also be asked to complete a series of
questionnaires on subjective sleep quality, sleep quantity, and daytime sleepiness.
Participants will complete five study visits, beginning 1 week from screening and separated
by 5 to 10 days to allow drug wash-out and recovery from effects of the previous visit. Each
study visit will involve an overnight stay in a sleep lab. Participants will arrive at 8 PM,
go to bed at 10 PM, and be awakened at 5 AM. Between 6 and 8 AM, they will undergo three
different tests, each corresponding to a different type of learning and memory process:
perceptual, motor, or declarative. The test will include recognizing a target image, typing
a specific finger sequence on a keyboard, and verbally recalling a list of words.
Participants will receive one of the study drugs or placebo at 8: 30 AM and then be allowed
to take a 90-minute nap between 9 and 11 AM. They will receive a different drug, different
dosage, or placebo at each study visit. Between 4 and 6 PM, they will be retested on the
previous three tests. While sleeping, participants will be outfitted with sensors monitoring
muscle activity, eye movements, brain waves, heart and lung functioning, and—on the first
night—breathing.
For the entire duration of the study, participants will wear an actigraph, which is a
wristwatch-like device that monitors sleep cycles. Participants will also be required to
maintain a regular sleep schedule, going to sleep and waking up in the same 2-hour window
each day. They will also report on sleep schedule and caffeine, alcohol, and drug use in a
daily sleep diary. Caffeine, alcohol, and drug use will be prohibited starting at noon on
the day prior to each study visit.
Eligibility
Minimum age: 18 Years.
Maximum age: 39 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Speaks English
- Resides in the general San Diego community
- Completed at least 12 years of formal education, because education may affect
performance on the cognitive task
Exclusion Criteria:
- No regular sleep-wake schedule, defined as not meeting study criteria or scoring
between 31 and 69 on the Horne-Ostberg Morningness-Eveningness Questionnaire
- Presence of a sleep disorder reported or detected on the questionnaires
- Personal or immediate family (i. e., first degree relative) history of diagnosed
significant psychopathology
- Personal history of head injury with loss of consciousness for more than 15 minutes
or with seizures
- History of substance dependence
- Current use of any psychotropic medications
- Any cardiac, respiratory, or other medical condition that may affect cerebral
metabolism
- Noncorrectable vision and audition impairments
Locations and Contacts
Jen Kanady, BA, Phone: 858-642-3192, Email: jkanady@ucsd.edu
UCSD General Clinical Research Center Laboratory for Sleep and Chronobiology (GCRC-LSC), La Jolla, California 92093, United States; Recruiting Jan Kanady, BA, Phone: 858-642-3192
Additional Information
Starting date: September 2008
Last updated: April 8, 2009
|